Preprocedural fasting for contrast-enhanced CT: when experience meets evidence

Liu, Heng; Liu, Yu; Zhao, Li; Li, Xue; Zhang, Weiguo

doi:10.1186/s13244-021-01131-1

Insights into Imaging

Table 2 Literature estimates of the incidence of nausea and vomiting symptoms in CECT examinations

From: Preprocedural fasting for contrast-enhanced CT: when experience meets evidence

Author (year) (ref)	Country	Total subjects	Data collection	Iodinated contrast medium used	Incidence (%)
Author (year) (ref)	Country	Total subjects	Data collection	Iodinated contrast medium used	Nausea	Vomiting
Katayama et al. (1990) [9]	Japan	337,647	Prospective	Ionic iodinated contrast medium	4.58%	1.84%
Katayama et al. (1990) [9]	Japan	337,647	Prospective	Non-ionic iodinated contrast medium	1.04%	0.36%
Oowaki et al. (1994) [12]	Japan	2414	Prospective	Amidotrizoic acid	6.7%
Oowaki et al. (1994) [12]	Japan	2414	Prospective	Iopamidol, Iohexol	1.4%
Geeter et al. (1994) [13]	Germany	198	Randomized phase III clinical trial	Iomeprol	2%	3%
Geeter et al. (1994) [13]	Germany	198	Randomized phase III clinical trial	Iopromide	3%	2%
Federle et al. (1998) [14]	USA	452	Prospective	Ioversol	1.99%	/
Morteléet et al. (2005) [15]	USA	29,508	Prospective	Iopromide	0.034%
Nagamoto et al. (2006) [16]	Japan	945	Prospective	Iopamidol	0.85%	/
Wendt-Nordahl et al. (2006) [17]	Germany	49,975	Prospective (PMS)	Iobitridol	0.3%	< 0.1%
Vogl et al. (2006) [18]	Germany	52,057	Prospective (PMS)	Iobitridol	0.24%	0.086%
Vijayalakshmi et al. (2007) [19]	United Kingdom	1985	Prospective	Iopamidol	0.39%	0.29%
Vijayalakshmi et al. (2007) [19]	United Kingdom	1985	Prospective	Iomeprol	0.73%	0.52%
Kopp et al. (2008) [20]	Multinational	74,717	Prospective (PMS)	Iopromide	0.54%
Gomi et al. (2010) [21]	Japan	8931	Prospective	Iopromide, Iomeprol, Iopamidol, Iohexol, Ioversol	0.3%
Häussler et al. (2010) [22]	Germany	9515	Prospective (PMS)	Iodixanol	0.12%	0.08%
Maurer et al. (2011) [23]	Germany	160,639	Prospective (PMS)	Iobitridol	0.20%	0.06%
García et al. (2013) [24]	Spain	110,041	Retrospective	Iopromide, Iomeprol	0.047%
Pradubpongsa et al. (2013) [25]	Thailand	55,286	Retrospective	/	0.166%
Zhang et al. (2013) [26]	China	20,185	Prospective (PMS)	Iodixanol	0.154%	0.089%
Müller (2014) [27]	Germany	10,354	Prospective (PMS)	Iodixanol	0.18%	0.05%
Palkowitsch et al. (2014) [28]	Multinational	132,012	Prospective (including PMS)	Iopromide	0.52%
Li et al. (2015) [29]	China	109,255	Retrospective	Iopromide, Iodixanol, Iopamidol, Iohexol, Ioversol	0.053%
Zhang et al. (2016)[30]	China	137,473	Retrospective	Iopromide, Iopamidol	0.023%	0.041%
Li et al. (2018) [11]	China	110,836	Prospective	Iopromide, Iodixanol, Iopamidol, Ioversol, Iobitridol, Iohexol	0.013%	0.059%
Kim et al. (2018) [31]	Korea	1175	Prospective	Iobitridol, Iohexol, Iomeprol, Iversol, Iopamidol	2.9%	0%
Ha et al. (2020) [32]	Korea	864	Retrospective	Iobitridol, Iohexol, Iomeprol, Ioversol, Iopamidol	0.69%	1.39%

None of these studies reported a single instance of vomiting-associated aspiration pneumonia
PMS, post-marketing surveillance

Back to article page